Yantai Zhenghai Biotechnology Co., Ltd. (SHE:300653)
China · Delayed Price · Currency is CNY 14.13
-0.16 (-1.12%)
Nov 6, 2026, 11:15 AM CST
SHE:300653 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 319.54 | 364.09 | 362.93 | 413.35 | 432.95 | 399.9 |
Other Revenue | 0.05 | 0.05 | 0.29 | 0.3 | 0.27 | 0.28 |
| 319.58 | 364.14 | 363.23 | 413.65 | 433.22 | 400.18 | |
Revenue Growth | -8.06% | 0.25% | -12.19% | -4.52% | 8.26% | 36.45% |
Cost of Revenue | 50.97 | 51.43 | 44.89 | 42.98 | 49.87 | 44.42 |
Gross Profit | 268.62 | 312.71 | 318.34 | 370.67 | 383.35 | 355.75 |
Selling, General & Admin | 151.97 | 177.18 | 147.9 | 132.04 | 145.55 | 151.39 |
Research & Development | 55.04 | 57.33 | 39.52 | 44.05 | 37.55 | 35.18 |
Other Operating Expenses | 7.52 | 5.16 | 3.9 | 3.86 | 3.87 | 3.93 |
Operating Expenses | 214.51 | 239.93 | 191.71 | 180 | 187.24 | 190.84 |
Operating Income | 54.1 | 72.78 | 126.63 | 190.68 | 196.12 | 164.91 |
Interest Expense | - | -0.01 | -0.01 | -0.01 | -0 | - |
Interest & Investment Income | 9.17 | 8.82 | 13.38 | 18.9 | 10.9 | 1.72 |
Other Non Operating Income (Expenses) | -0.45 | -0.03 | -0.21 | -0.34 | 0.19 | -0.04 |
EBT Excluding Unusual Items | 62.82 | 81.57 | 139.78 | 209.23 | 207.21 | 166.59 |
Gain (Loss) on Sale of Investments | 5.18 | 5.11 | 5.43 | 7.3 | -2.79 | 15.94 |
Gain (Loss) on Sale of Assets | -0.06 | -0.06 | -0.08 | 0.02 | -0.92 | - |
Asset Writedown | - | - | - | -0.12 | -0.11 | -0.19 |
Other Unusual Items | 1.23 | 1.51 | 7.24 | 1.97 | 8.73 | 9.23 |
Pretax Income | 69.17 | 88.13 | 152.38 | 218.4 | 212.11 | 191.58 |
Income Tax Expense | 5.4 | 5.72 | 17.74 | 27.44 | 26.67 | 23.03 |
Net Income | 63.76 | 82.41 | 134.64 | 190.96 | 185.44 | 168.55 |
Net Income to Common | 63.76 | 82.41 | 134.64 | 190.96 | 185.44 | 168.55 |
Net Income Growth | -16.83% | -38.79% | -29.49% | 2.98% | 10.02% | 42.44% |
Shares Outstanding (Basic) | 178 | 179 | 180 | 180 | 145 | 179 |
Shares Outstanding (Diluted) | 178 | 179 | 180 | 180 | 145 | 179 |
Shares Change | -0.81% | -0.20% | -0.35% | 24.35% | -19.21% | 0.01% |
EPS (Basic) | 0.36 | 0.46 | 0.75 | 1.06 | 1.28 | 0.94 |
EPS (Diluted) | 0.36 | 0.46 | 0.75 | 1.06 | 1.28 | 0.94 |
EPS Growth | -16.14% | -38.67% | -29.24% | -17.19% | 36.17% | 42.42% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 53.35 | 88.09 | 135.81 | 148.6 | 131.78 | 156.31 |
Free Cash Flow Per Share | 0.30 | 0.49 | 0.76 | 0.82 | 0.91 | 0.87 |
Dividend Per Share | 0.280 | 0.280 | 0.460 | 0.802 | 0.600 | 0.587 |
Dividend Growth | -39.13% | -39.13% | -42.63% | 33.63% | 2.27% | 251.95% |
Gross Margin | 84.05% | 85.88% | 87.64% | 89.61% | 88.49% | 88.90% |
Operating Margin | 16.93% | 19.99% | 34.86% | 46.10% | 45.27% | 41.21% |
Profit Margin | 19.95% | 22.63% | 37.07% | 46.16% | 42.80% | 42.12% |
Free Cash Flow Margin | 16.69% | 24.19% | 37.39% | 35.92% | 30.42% | 39.06% |
EBITDA | 76.2 | 95.09 | 149.22 | 211.19 | 215.22 | 182.65 |
EBITDA Margin | 23.84% | 26.11% | 41.08% | 51.06% | 49.68% | 45.64% |
D&A For EBITDA | 22.1 | 22.31 | 22.59 | 20.52 | 19.1 | 17.74 |
EBIT | 54.1 | 72.78 | 126.63 | 190.68 | 196.12 | 164.91 |
EBIT Margin | 16.93% | 19.99% | 34.86% | 46.10% | 45.27% | 41.21% |
Effective Tax Rate | 7.81% | 6.49% | 11.64% | 12.56% | 12.57% | 12.02% |
Revenue as Reported | 88.42 | 364.14 | 363.23 | 413.65 | 433.22 | 400.18 |
Advertising Expenses | - | 1.92 | 4.19 | 3.33 | 4.06 | 5.11 |